KALA BIO, Inc.
NCM: KALALive Quote
About KALA BIO, Inc.
Healthcare
Biotechnology
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
📊 Fundamental Analysis
KALA BIO, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
At a current price of $0.20, KALA currently trades near the bottom of its 52-week range (0%), indicating potential value or weakness (Range: $0.15 - $20.60).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$43.69M
Trailing P/E
--
Forward P/E
-0.03
Beta (5Y)
-1.99
52W High
$20.60
52W Low
$0.15
Avg Volume
7.06M
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App